SCHEDULE 13G/A: Adage Capital Management Discloses Continued 7.13% Stake in TScan Therapeutics
Beneficial Ownership Report
Adage Capital Management, L.P. and its principals have reported an updated 7.13% beneficial ownership stake in TScan Therapeutics, Inc. as of December 31, 2024, through an amended Schedule 13G filing.
Summary
- Adage Capital Management, L.P., along with its managing members Robert Atchinson and Phillip Gross, collectively reported beneficial ownership of 3,500,000 shares of TScan Therapeutics, Inc. Voting Common Stock.
- This ownership represents 7.13% of the company's outstanding shares, calculated based on 49,094,006 shares of Voting Common Stock outstanding as of November 7, 2024.
- The filing is an Amendment No. 2 to a Schedule 13G, indicating an update to a previously disclosed ownership position.
- The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing the control of TScan Therapeutics.
- Adage Capital Partners GP, L.L.C. is explicitly stated as no longer being a beneficial owner of securities held by ACP.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, carrying a neutral sentiment. It neither indicates positive nor negative operational news for the issuer, TScan Therapeutics.
Positives
- A significant institutional investor, Adage Capital Management, maintains a substantial stake in TScan Therapeutics, which may signal continued confidence in the company's long-term prospects.
- The filing confirms the investment is held in the ordinary course of business and not for control purposes, suggesting a passive, long-term investment approach.
Future Outlook
NA
Industry Context
This filing represents a routine disclosure of a significant institutional investment in TScan Therapeutics, a company operating within the biotechnology and therapeutics sector. Such disclosures are standard for large investment firms managing diversified portfolios and provide transparency regarding major shareholder positions.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, which can influence market perception and liquidity.
Key Dates
| Date | Description |
|---|---|
| 2024-11-07 | Date as of which 49,094,006 shares of Voting Common Stock were reported outstanding in TScan Therapeutics' Quarterly Report on Form 10-Q. |
| 2024-12-31 | Date of event which requires filing of this statement (reporting period end date for beneficial ownership). |
| 2025-02-12 | Date of filing of this Schedule 13G Amendment No. 2. |
Keywords
TScan Therapeutics, Adage Capital Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Voting Common Stock, SEC Filing, Investment Management, Biotechnology, Therapeutics
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.